What do you mean by Cancer Treatment Pathway?
Pathways are widely accepted as a component in managing oncology treatment quality and costs. More specific than guidelines, pathways identify treatments selected based on effectiveness, favorable toxicity profiles, and cost. Over half of practices responding to ASCO’s 2010 National Practice Benchmark report that they regularly use pathways in patient care. Organizations that have implemented pathways have found that survival outcomes are equivalent for patients treated on and off pathway, while treatment costs decrease substantially for patients treated on pathway.
How were the Cancer Treatment Pathways developed?
The goal of the Cancer Care Quality Program is to promote access to quality and affordable cancer care for health plan members. A key component of the Cancer Care Quality Program is the development of the Amerigroup Cancer Treatment Pathways.
Cancer Treatment Pathways are developed using a rigorous process of evidence-based medicine. In order to be considered as a possible Cancer Treatment Pathway, a cancer treatment regimen must first be recognized by national guidelines as an effective and recommended cancer therapy.
The Pathways are developed starting with the medical evidence and national clinical guidelines, such as NCCN and ASCO guidelines, which also are used for developing Amerigroup medical policy. The Pathways are then reviewed by an external Advisory committee that consist of geographically diverse physicians who are actively treating patients and work in academic and community oncology groups. The committee uses a process similar to how we evaluate drugs chosen for our drug formularies. The group evaluates the evidence for given treatments and compares outcomes for each – much like a comparative effectiveness review. Then, they compare costs of those regimens with the best outcomes.
How are Amerigroup’s external Advisors selected?
Our advisors are selected because of their clinical expertise in cancer care. Of the physicians currently serving as advisors for Amerigroup, some are on the staffs of NCI or NCCN designated cancer centers, including Cleveland Clinic, Columbia, Fred Hutchinson, University of Colorado, and Yale and some are in community practice settings; many serve or have served on national committees for organizations such as NQF, ASCO, FACT, and IOM to improve cancer care.
Does Amerigroup have a process to manage conflicts of interest for external Advisors?
Amerigroup is committed to having clinical experts free of commercial bias and conflicts of interest determining which treatment regimens to be included in Pathways. Upon agreeing to serve as advisors for Amerigroup, advisors must sign a formal Agreement that outlines the responsibilities, including an acknowledgment that advisor has no conflict of interest. Advisors also agree to notify Amerigroup immediately of the existence of any conflict of interest. Additionally, advisors must sign a new conflict of interest attestation, at least once annually.
The Cancer Treatment Pathways are selected on the basis of:
- Clinical benefit (efficacy)
- Side-effects (toxicity), especially those that lead to hospitalizations or impact quality of life
- Strength of national guideline recommendations
Cost is considered only after consideration of all other factors in selecting a therapy as a Cancer Treatment Pathway.
What types of cancer have Pathways eligible for enhanced reimbursement?
As of September 1, 2016, Cancer Care Quality Program will include Cancer Treatment Pathways for the following cancer types:
- Bladder Cancer
- Breast Cancer (Neo/Adv, Metastatic, Endocrine)
- Central Nervous System (CNS)
- Chronic Myelogenous Leukemia (CML)
- Colorectal Cancer
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma and Marginal Zone Lymphoma
- Gastroesophageal Cancer
- Head and Neck Cancer
- Hodgkin’s Lymphoma
- Kidney Cancer
- Mantle Cell Lymphoma
- Non-Small Cell Lung Cancer
- Ovarian Cancer
- Pancreatic Cancer (Adenocarcinoma)
- Prostate Cancer
- Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia
We will be adding additional Pathways for other common malignancies throughout 2015.
Providers are encouraged to enter regimens for all malignancies into the ProviderPortal.
Where can I find a copy of the Cancer Treatment Pathways?
The pathways are posted on www.cancercarequality.com. On this website you can find information, tools and worksheets to assist you in incorporating the Cancer Care Quality Program into your practice.
What if I am treating a patient for whom a Pathway regimen option is not available?
Cancer Treatment Pathways include multiple regimens for different clinical situations. However, if a Pathway regimen is not available for a particular type of cancer or line of therapy, you can select a different regimen.
Do Pathways apply to pediatric patients?
The Cancer Care Quality Program only applies to adult oncology patients at this time. However, you are encouraged to enter regimens for all malignancies into the ProviderPortal.
What happens if I do not select a treatment regimen that is designated as a Cancer Treatment Pathway?
The requested treatment regimen will continue to be reviewed through the usual utilization management review process if UM is required and/or adjudicated according to the member’s benefit plan.
How often are the Cancer Treatment Pathways updated?
Cancer Treatment Pathways are reviewed at least quarterly or more frequently, as needed.
Are supportive drugs included in the Pathways?
Supportive care drugs, such as those used to manage side effects of chemotherapy, are not currently included in the Cancer Treatment Pathways. However, the entire cancer treatment drug regimen, including supportive care drugs, should be included in the order request as certain supportive drugs may be included on the list of drugs that require utilization management review against applicable health plan medical policies or clinical guidelines. This list has not changed with the introduction of the Cancer Care Quality Program.